News >

Locke Highlights Axi-Cel/Atezolizumab Data in DLBCL

Angelica Welch
Published: Thursday, Feb 01, 2018

Frederick L. Locke, MD

Frederick L. Locke, MD
The combination of axicabtagene ciloleucel (axi-cel; Yescarta) and atezolizumab (Tecentriq) was deemed to be active and have a manageable safety profile in patients with refractory diffuse large B-cell lymphoma (DLBCL), according to findings from the phase I/II ZUMA-6 trial presented at the 2017 ASH Annual Meeting.

, Locke, a medical oncologist at Moffitt Cancer Center, discussed the initial data for axi-cel plus atezolizumab in DLBCL and reflected on the long-term survival data from the ZUMA-1 trial.

OncLive: Can you provide some background on the ZUMA-6 trial?

Locke: The ZUMA-6 study is a trial combining the CD19-directed CAR T-cell therapy axi-cel with the PD-L1 antibody atezolizumab. This trial is enrolling patients with DLBCL who did not respond to their last line of chemotherapy or who progressed within 12 months of an autologous hematopoietic stem cell transplant.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication